Status:
UNKNOWN
Trans-arterial Chemoembolization in Patients With Hepatocellular Carcinoma: A Study of Different Outcomes and Their Predictive Factors
Lead Sponsor:
Assiut University
Conditions:
Liver Cancer
Eligibility:
All Genders
40+ years
Brief Summary
Radiological response after trans arterial chemoembolization (TACE) is classified according to Modified Response Evaluation Criteria in Solid Tumors (mRECIST) to: complete response (CR) (disappearance...
Detailed Description
POST-TACE response of treatment for cases of hepatocellular cancer
Eligibility Criteria
Inclusion
- Clinical history and examination with special stress on symptoms and signs of chronic liver disease with or without evidence of hepatic decompensation e.g. the presence of ascites and with or without evidence of complications e.g. jaundice spider naevi, bleeding varices, ascites, and lower limb edema.
- Laboratory findings in the form of raised bilirubin and liver enzymes, impaired coagulation profile, and/or low serum albumin.
- Abdominal ultrasonography revealing liver cirrhosis (coarse echopattern, attenuated hepatic veins, irregular outlines, hypertrophy of caudate lobe and/or shrunken liver, presence of focal hepatic) and presence of splenomegaly, ascites, or portal vein thrombosis (PVT).
Exclusion
- A patient who had surgical resection or liver transplantation Patients refuse to participate Hepatic focal lesion other than HCC
Key Trial Info
Start Date :
December 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 30 2022
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04739501
Start Date
December 1 2020
End Date
March 30 2022
Last Update
February 4 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Assiut
Asyut, Egypt, 71515